IN2014DN10404A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN10404A IN2014DN10404A IN10404DEN2014A IN2014DN10404A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A IN 10404DEN2014 A IN10404DEN2014 A IN 10404DEN2014A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A
- Authority
- IN
- India
- Prior art keywords
- pde7
- addictions
- phosphodiesterase
- directed
- disclosure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Addiction (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261643611P | 2012-05-07 | 2012-05-07 | |
US13/835,607 US9220715B2 (en) | 2010-11-08 | 2013-03-15 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
PCT/US2013/039866 WO2013176877A2 (en) | 2012-05-07 | 2013-05-07 | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN10404A true IN2014DN10404A (ko) | 2015-08-14 |
Family
ID=49624481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN10404DEN2014 IN2014DN10404A (ko) | 2012-05-07 | 2013-05-07 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2846805B1 (ko) |
JP (1) | JP2015521177A (ko) |
CN (3) | CN112168972A (ko) |
AU (1) | AU2013266793B2 (ko) |
CA (1) | CA2871151C (ko) |
IN (1) | IN2014DN10404A (ko) |
PL (1) | PL2846805T3 (ko) |
RS (1) | RS58381B1 (ko) |
SI (1) | SI2846805T1 (ko) |
WO (1) | WO2013176877A2 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014504271A (ja) | 2010-11-08 | 2014-02-20 | オメロス コーポレーション | Pde7インヒビターを用いる嗜癖および衝動制御障害の処置 |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
US20190185479A1 (en) | 2016-08-26 | 2019-06-20 | Mitsubishi Tanabe Pharma Corporation | Bicyclic nitrogenated heterocyclic compound |
WO2023243659A1 (ja) * | 2022-06-15 | 2023-12-21 | 真一 松本 | 線条体ストリオソームのドパミンd1シグナルを標的とした強迫性障害の薬物療法 |
WO2024038090A1 (en) * | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1775298B1 (en) * | 2004-07-01 | 2013-03-20 | Daiichi Sankyo Company, Limited | Thienopyrazole derivative having pde7 inhibitory activity |
US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
PT1928438E (pt) * | 2005-09-26 | 2013-04-03 | Avigen Inc | Método para tratamento de dependências de drogas e comportamentos |
WO2008119057A2 (en) * | 2007-03-27 | 2008-10-02 | Omeros Corporation | The use of pde7 inhibitors for the treatment of movement disorders |
US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
US8426439B2 (en) * | 2007-04-11 | 2013-04-23 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
FR2943673B1 (fr) * | 2009-03-27 | 2013-03-29 | Sanofi Aventis | Applications therapeutiques de derives de quinazolinedione |
FR2944282B1 (fr) * | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
JP2014504271A (ja) * | 2010-11-08 | 2014-02-20 | オメロス コーポレーション | Pde7インヒビターを用いる嗜癖および衝動制御障害の処置 |
-
2013
- 2013-05-07 RS RS20190228A patent/RS58381B1/sr unknown
- 2013-05-07 CN CN202011054538.2A patent/CN112168972A/zh active Pending
- 2013-05-07 IN IN10404DEN2014 patent/IN2014DN10404A/en unknown
- 2013-05-07 JP JP2015511605A patent/JP2015521177A/ja active Pending
- 2013-05-07 PL PL13793319T patent/PL2846805T3/pl unknown
- 2013-05-07 SI SI201331354T patent/SI2846805T1/sl unknown
- 2013-05-07 CN CN201380036048.1A patent/CN104768556A/zh active Pending
- 2013-05-07 CA CA2871151A patent/CA2871151C/en active Active
- 2013-05-07 WO PCT/US2013/039866 patent/WO2013176877A2/en active Application Filing
- 2013-05-07 EP EP13793319.8A patent/EP2846805B1/en active Active
- 2013-05-07 AU AU2013266793A patent/AU2013266793B2/en active Active
- 2013-05-07 CN CN202210569437.1A patent/CN114984229A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2846805A4 (en) | 2016-08-10 |
CN114984229A (zh) | 2022-09-02 |
CA2871151C (en) | 2019-03-26 |
WO2013176877A3 (en) | 2015-06-18 |
CN104768556A (zh) | 2015-07-08 |
CN112168972A (zh) | 2021-01-05 |
WO2013176877A2 (en) | 2013-11-28 |
EP2846805A2 (en) | 2015-03-18 |
SI2846805T1 (sl) | 2019-04-30 |
CA2871151A1 (en) | 2013-11-28 |
RS58381B1 (sr) | 2019-04-30 |
EP2846805B1 (en) | 2018-11-21 |
AU2013266793B2 (en) | 2016-08-04 |
PL2846805T3 (pl) | 2019-05-31 |
AU2013266793A1 (en) | 2014-11-27 |
JP2015521177A (ja) | 2015-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4275752A3 (en) | Treatment of addiction and impulse-control disorders using pde7 inhibitors | |
HK1205938A1 (en) | Inhibitors of human ezh2, and methods of use thereof ezh2 | |
MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
EP2836270A4 (en) | SYSTEMS AND METHODS RELATED TO THE TREATMENT OF BACK PAIN | |
MX351464B (es) | El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas. | |
PH12015502302B1 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
IN2014CN04014A (ko) | ||
IN2014DN10404A (ko) | ||
PL2780025T3 (pl) | Zastosowanie ekstraktów z wiązówki (Filipendula) do leczenia i profilaktyki przewlekłych stanów bólowych | |
MX2013002121A (es) | Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
MX2014004991A (es) | Combinaciones terapeuticas y metodos para tratar el melanoma. | |
MX2016003293A (es) | Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados. | |
MX2016005614A (es) | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. | |
HK1223014A1 (zh) | 用於在預防和/或治療多動性運動障礙中使用的治療劑 | |
MX356052B (es) | Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion. | |
EP2710017A4 (en) | MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT | |
HRP20181746T1 (hr) | Trpc4 modulatori za uporabu u liječenju ili prevenciji bola | |
CO7151515A2 (es) | Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina | |
WO2012097121A9 (en) | Specific nnos inhibitors for the therapy and prevention of human melanoma | |
HRP20190279T1 (hr) | Liječenje ovisnosti i poremećaja nagona pomoću pde7 inhibitora | |
HK1209073A1 (en) | Plod-2 stimulators and their use in the treatment of skin plod-2 | |
AU2013101402A4 (en) | Timber treatment formulations and methods of use | |
MX2013006527A (es) | Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos. |